Skip to content
Evigrade
CriticalAntiviral for systemic use, HIV-1 protease inhibitor; used only with a pharmacokinetic booster (ritonavir or cobicistat)×HMG-CoA reductase inhibitor (statin)

Updated · Methodology

Mechanism

The liver clears lovastatin through the enzyme CYP3A4. Strong inhibitors of this enzyme raise lovastatin blood levels and with them the risk of muscle damage (myopathy) and muscle breakdown (rhabdomyolysis) (lovastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Darunavir is taken only with a booster, ritonavir or cobicistat, and in this regimen it inhibits CYP3A (darunavir SmPC, European Medicines Agency, EMA; darunavir label, US Food and Drug Administration, FDA). The pair has not been studied, but lovastatin levels are expected to rise markedly (darunavir SmPCs, AEMPS and EMA). Human immunodeficiency virus (HIV) protease inhibitors, the class darunavir belongs to, appear by name among the strong CYP3A4 inhibitors in the lovastatin SmPC (lovastatin SmPC, AEMPS).

Symptoms

Myopathy shows as muscle pain, tenderness or weakness with creatine kinase (CK) above ten times the upper limit of normal (lovastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). It sometimes progresses to rhabdomyolysis with acute kidney failure caused by myoglobin in the urine, in rare cases fatal (lovastatin SmPC, AEMPS). Muscle pain, tenderness or weakness is of particular concern when it comes with malaise or fever (lovastatin label, US Food and Drug Administration, FDA). Since darunavir came to market, rhabdomyolysis linked to co-administration with statins has been reported (darunavir/cobicistat FDA label).

Management

The combination is contraindicated. Lovastatin is on the darunavir list of contraindicated drugs (darunavir summary of product characteristics, SmPC, European Medicines Agency, EMA; darunavir label, US Food and Drug Administration, FDA). Under the lovastatin documents, lovastatin must not be used with any human immunodeficiency virus (HIV) protease inhibitor (lovastatin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; lovastatin FDA label). The contraindication applies with either booster, ritonavir or cobicistat, including the fixed-dose darunavir/cobicistat tablet (darunavir and darunavir/cobicistat SmPCs, EMA; darunavir and darunavir/cobicistat FDA labels). If the patient needs a statin during darunavir treatment, start atorvastatin at 10 mg once daily and increase the dose gradually according to clinical response (darunavir SmPC, AEMPS). With darunavir/cobicistat, start any statin other than lovastatin and simvastatin at the lowest dose and titrate it while monitoring safety (darunavir/cobicistat SmPC, EMA). Keep atorvastatin and rosuvastatin at no more than 20 mg a day (darunavir/cobicistat FDA label). Tell the patient to report unexplained muscle pain, tenderness or weakness at once (lovastatin SmPC, AEMPS). If the patient has nevertheless taken lovastatin with darunavir and muscle symptoms appear, measure creatine kinase (CK). Stop lovastatin if CK is above 5 times the upper limit of normal in the absence of strenuous exercise (lovastatin SmPC, AEMPS). If myopathy is suspected, stop lovastatin at once. In most cases, muscle symptoms and CK rises resolved after prompt withdrawal (lovastatin FDA label).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Darunavir

Other interactions with Lovastatin